Phase II/III pivotal trial of NB-1001 in patients with short bowel syndrome

Trial Profile

Phase II/III pivotal trial of NB-1001 in patients with short bowel syndrome

Planning
Phase of Trial: Phase II/III

Latest Information Update: 11 Mar 2016

At a glance

  • Drugs NB 1001 (Primary)
  • Indications Short bowel syndrome
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 11 Mar 2016 According to a Naia Rare Diseases media release, the company plans to file an IND for NB-1001 in the second quarter of 2016, and expects this II/III study to be required for product approval.
    • 14 Oct 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top